Biosimilars Uptake & Patient Safety

Biosimilar engineers and their outsourcing accomplices must know about the picked nation's administrative scene, and have broad information of any current biosimilar endorsement pathway and the most recent administrative organization rules. Furnishing administrative experts with endorsements of investigation (CoA) for a U.S.- advertised comparator could challenge. As opposed to European practice, U.S. makers tend not to make CoAs accessible to parties required in the production network or bolster the improvement of a contender by discharging CoAs for clumps acquired for clinical trials. Giving family proclamations to the reference item more often than not is acknowledged as an option.

  • Case studies of biosimilar approvals/rejections
  • Challenges in clinical development
  • Analytical Development and Quality Control

Related Conference of Biosimilars Uptake & Patient Safety

October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
February 28-March 01, 2019

Global Pharmaceutical & Pharma Industry Conference

Osaka, Japan
March 18-19, 2019

13th International Conference on Biosimilars and Biologics

Amsterdam | Netherlands
August 5-6, 2019

13th Asian Biologics and Biosimilars Congress

Melbourne, Australia

Biosimilars Uptake & Patient Safety Conference Speakers

Recommended Sessions

Related Journals

Are you interested in